Chronic Neuropathic Pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7–10% of the general population. Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy.
Chronic Neuropathic Pain Market may result from disorders of the peripheral nervous system or the central nervous system (brain and spinal cord). Thus, neuropathic pain may be divided into peripheral neuropathic pain, central neuropathic pain, or mixed (peripheral and central) neuropathic pain.
Examples of the peripheral neuropathic pain include diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN), antineoplastic therapy or HIV-induced sensory neuropathy, tumor infiltration neuropathy, phantom limb pain, postmastectomy pain, complex regional pain syndromes (reflex sympathetic dystrophy), and trigeminal neuralgia.
Central neuropathic pain results include multiple sclerosis (MS), spinal cord injury (SCI), central post stroke pain, and Parkinson disease. Neuropathic pain is usually caused by chronic, progressive nerve disease, and it can also occur as the result of injury or infection. Chronic neuropathic pain, can flare up at any time without an obvious pain-inducing event or factor.
Acute neuropathic pain which is uncommon, can occur as well. All neuropathic pain that are labelled as chronic have a history of an acute phase, that is, before the first 3 months have elapsed, a time line agreed upon by the International Association for the Study of Pain and the WHO.
For More Info- Chronic Neuropathic Pain market research
The treatment initially focuses on resolving the underlying cause. Medications used to treat neuropathic pain include over-the-counter analgesics, anticonvulsants, tricyclic antidepressants (TCAs), topical anesthetic agents, nonsteroidal anti-inflammatory drugs (NSAIDs), antiarrhythmics, narcotic analgesics, and opioids.
According to the International Association for the Study of Pain, neuropathic pain is characterized by a “pain arising as a direct consequence of a lesion or disease of the somatosensory system”.
The existing literature has primarily investigated the epidemiology of neuropathic pain within the context of specific diseases, such as cancer, diabetic peripheral neuropathy (DPN), and chronic low-back pain (CLBP). The study by Bouhassira et al. (2019), have shown that the prevalence of neuropathic pain in the general population may be as high as 7–8%, accounting for 20–25% of individuals with chronic pain.
As per the study conducted by Yawn et al. (2009), titled “The prevalence of neuropathic pain: Clinical evaluation compared with screening tools in a community population,” the prevalence of chronic neuropathic pain based on clinical examination is 9.8% in the US.
The 9.8% community prevalence rate from the clinical examination represents 15.2% of those with self-reported chronic pain of greater than 3 months duration. This 15.2% of the Olmsted County population with chronic neuropathic pain corresponds to the 17.0% reported n the UK population.
As per the article by Yu et al. (2020), titled “Neuromodulation Management of Chronic Neuropathic Pain in the Central Nervous System,” chronic neuropathic pain is a widespread condition that affects 7–8% of the total population.
The study conducted by Chenafa et al. (2018), titled “Prevalence of chronic pain with or without neuropathic characteristics in France using the capture–recapture method: a population-based study,” show that the estimated prevalence of chronic neuropathic pain in the adults ranged from 5.55–7.30%.
The patients included 35.9% males and 64.1% females. The age group <25, 25–34, 35–49, 50–64, 65–74 and ≥75 years represents 0.6%, 3.6%, 17.5%, 31.2%, 19.6%, and 27.5% of total cases.
According to an article by Melillo (2020), published on the American Journal of Managed Care, in France the prevalence of chronic neuropathic pain is around 6.9%.
Read More- Chronic Neuropathic Pain Market Insight
Comments
Post a Comment